As of November 6, 2026, Palvella Therapeutics, Inc. is a publicly traded company (Nasdaq: PVLA); its largest reported holder is Jennison Associates LLC, with 7.7% on Schedule 13G/A of October 28, 2026, then Suvretta Capital Management, LLC (7.4%). The largest insider holding is George M. Jenkins, a director, with 146,132 shares (1.00% of shares outstanding), per Form 4 of October 14, 2026 (Schedule 13G/A, October 28, 2026).
Is this your company?
About to sign with, pay or invest in Palvella Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Palvella Therapeutics, Inc. a real, registered company?
- Palvella Therapeutics Inc files with the SEC under CIK 1583648 (its SEC filings).
- Its shares are listed under the ticker PVLA on Nasdaq (SEC company record).
- Incorporated in Nevada; business address in Wayne, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under PALVELLA THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Matthew Pauls, Director (Form 8-K filed 2026-06-30). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Jennison Associates LLC (filed 2026-10-28).
Who are Palvella Therapeutics, Inc.'s owners and officers?
Palvella Therapeutics, Inc.: incorporated in Nevada; business address in Wayne, Pennsylvania; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-28).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-28 | Jennison Associates LLC | 7.7% |
| Schedule 13G/A, 2026-08-14 | First Light Asset Management, LLC | 5.34% |
| Schedule 13G/A, 2026-08-14 | Bvf Partners L P/Il | 4.7% |
| Schedule 13G, 2026-08-10 | Prudential Financial Inc | 6.7% |
| Schedule 13G, 2026-08-03 | Jennison Associates LLC | 6.7% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.7% |
| Schedule 13G, 2026-02-17 | First Light Asset Management, LLC | 7.49% |
| Schedule 13G/A, 2026-02-17 | Bvf Partners L P/Il | 7.1% |
| Schedule 13G/A, 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 6% |
| Schedule 13G/A, 2025-11-14 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G/A, 2025-11-13 | Suvretta Capital Management, LLC | 7.4% |
| Schedule 13G/A, 2025-08-14 | Samsara Biocapital, L.P. | 3.1% |
Questions about who owns Palvella Therapeutics, Inc.
Who owns Palvella Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Palvella Therapeutics, Inc.: Jennison Associates LLC (7.7%, Schedule 13G/A, filed 2026-10-28), Suvretta Capital Management, LLC (7.4%, Schedule 13G/A, filed 2025-11-13), Prudential Financial Inc (6.7%, Schedule 13G, filed 2026-08-10), Frazier Life Sciences Public Fund, L.P. (6%, Schedule 13G/A, filed 2026-02-13) and Blackrock, Inc. (5.7%, Schedule 13G, filed 2026-07-29); 1 more is listed above.
Who are the largest shareholders of Palvella Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Palvella Therapeutics, Inc. on this page are Jennison Associates LLC (7.7%), Suvretta Capital Management, LLC (7.4%) and Prudential Financial Inc (6.7%).
When did Jennison Associates LLC buy into Palvella Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Jennison Associates LLC on this page is the Schedule 13G, filed 2026-08-03, reporting 6.7%; its latest, Schedule 13G/A filed 2026-10-28, reports 7.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Palvella Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Palvella Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Palvella Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
22 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-30 | Matthew Pauls | Director | appointed | |
| Form 8-K, 2026-04-13 | John Doux | Director | appointed |
Which insiders own Palvella Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 146,132 shares (1.00% of shares outstanding), 132,616 held directly and 13,516 indirectly (Form 4, 2026-10-14).
- Dellora Investments LP, a 10% owner: 141,079 shares (0.97% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 3, 2024-11-18).
- , a director: 112,547 shares (0.77% of shares outstanding) (Form 3, 2024-12-16).
- , a director: 53,691 shares (0.37% of shares outstanding), 47,812 held directly and 5,879 indirectly (Form 4, 2026-03-02).
- , the chief executive and president: 44,410 shares (0.30% of shares outstanding) (Form 3/A, 2025-01-06).
Shares outstanding: 14,618,457 as of 2026-11-02, from the company's latest SEC cover page.
How much has Palvella Therapeutics, Inc. raised?
Latest IPO step: Palvella Therapeutics, Inc. amended its IPO registration (S-1/A, 2025-01-14).
IPO filings: S-1/A, 2025-01-14, S-1, 2024-12-31; ticker PVLA on Nasdaq Capital Market.
Keep reading
More on Palvella Therapeutics, Inc. and the records around it.
Palvella Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Jun 2026
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), TriSalus Life Sciences, Inc. (Jul 2026)
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), REZOLUTE INC (Oct 2026), NEUROGENE INC (Oct 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/palvella-therapeutics